1.提案的理由
歐洲議會(huì)和理事會(huì)的第 2017/746 號(hào)條例 (EU) 為體外診斷醫(yī)療器械建立了新的監(jiān)管框架。新法規(guī) (EU) 2017/746原定于2022年5月26日起取代現(xiàn)行的體外診斷醫(yī)療器械指令 98/79/EC,并對(duì)該行業(yè)進(jìn)行重大變革。
原文:The Commission recognises the need to ensure both a high level of safety and performance of devices, and their availability on the EU market. The proposal therefore aims to extend the existing transitional period for devices covered by a certificate issued under Directive 98/79/EC and to introduce tailored transitional periods for devices that have to undergo a conformity assessment involving notified bodies for the first time under Regulation (EU) 2017/746. As, since its outbreak, many health institutions, in particular hospitals, have had to focus all their efforts on dealing with COVID-19, the Commission proposes to also introduce a transitional period for the requirements for devices manufactured and used within the same health institution (‘in-house devices’).
歐盟委員會(huì)意識(shí)到需要確保器械高水平的安全性和性能,以及它們?cè)跉W盟市場(chǎng)上的可用性,因此,頒布該提案旨在延長根據(jù)指令98/79/EC頒發(fā)證書所涵蓋的器械的現(xiàn)有過渡期,并為根據(jù)法規(guī)(EU) 2017/746首次必須經(jīng)過公告機(jī)構(gòu)的合格評(píng)定的器械引入量身定制的過渡期。由于自疫情爆發(fā)以來,許多衛(wèi)生機(jī)構(gòu),特別是醫(yī)院,投入了所有努力集中在應(yīng)對(duì)COVID-19上,因此,委員會(huì)還提議對(duì)同一衛(wèi)生機(jī)構(gòu)制造和使用的設(shè)備(“廠內(nèi)器械”)的要求引入一個(gè)過渡時(shí)期。
2.過渡性規(guī)定及延期
原文:Given the unprecedented magnitude of the current challenges, the additional resources needed from Member States, notified bodies, economic operators, health institutions and other relevant parties in order to fight the COVID-19 pandemic and the current limited capacity of notified bodies, and taking into account the complexity of Regulation (EU) 2017/746, it is very likely that Member States, health institutions, notified bodies, economic operators and other relevant parties will not be in a position to ensure the proper implementation and full application of that Regulation from 26 May 2022 as laid down therein.
鑒于當(dāng)前挑戰(zhàn)的規(guī)??涨埃瑫?huì)員國、公告機(jī)構(gòu)、經(jīng)濟(jì)運(yùn)營商、衛(wèi)生機(jī)構(gòu)和其他相關(guān)方需要額外資源以抗擊 COVID-19 大流行和公告機(jī)構(gòu)目前有限的能力,并考慮到 考慮到法規(guī) (EU) 2017/746 的復(fù)雜性,成員國、衛(wèi)生機(jī)構(gòu)、公告機(jī)構(gòu)、經(jīng)濟(jì)運(yùn)營商和其他相關(guān)方很可能無法確保該法規(guī)的正確實(shí)施和全面應(yīng)用其中規(guī)定的 2022 年 5 月 26 日。
原文:In order to ensure the smooth functioning of the internal market and a high level of protection of public health and patient safety, as well as to provide legal certainty and avoid potential market disruption, it is necessary to extend the transitional periods laid down in Regulation (EU) 2017/746 for devices covered by certificates issued by notified bodies under Directive 98/79/EC.For the same reasons, it is also necessary to provide a sufficient transitional period for devices which are to undergo conformity assessment involving a notified body for the first time under Regulation (EU) 2017/746.
為了確保內(nèi)部市場(chǎng)的平穩(wěn)運(yùn)行和對(duì)公眾健康和患者安全的高度保護(hù),以及提供法律確定性并避免潛在的市場(chǎng)混亂,有必要延長法規(guī)(EU) 2017/746中規(guī)定的,由公告機(jī)構(gòu)根據(jù)指令98/79/EC頒發(fā)證書所覆蓋器械的過渡期。出于同樣的原因,還需要為根據(jù)法規(guī) (EU) 2017/746 首次接受指定機(jī)構(gòu)參與的合格評(píng)定的器械提供足夠的過渡期。
原文:Therefore, the transitional periods for in vitro diagnostic medical devices that are to undergo conformity assessment involving a notified body for the first time under Regulation (EU) 2017/746 should differentiate between higher and lower risk devices. The length of the transitional period should depend on the risk class of the device concerned so that the period is shorter for devices of a higher risk and longer for devices of a lower risk class.
因此,根據(jù)法規(guī) (EU) 2017/746 首次接受指定機(jī)構(gòu)的合格評(píng)定的體外診斷醫(yī)療器械的過渡期應(yīng)區(qū)分高風(fēng)險(xiǎn)和低風(fēng)險(xiǎn)器械。過渡期的長短應(yīng)取決于相關(guān)器械的風(fēng)險(xiǎn)等級(jí),對(duì)于高風(fēng)險(xiǎn)器械的過渡期較短,而低風(fēng)險(xiǎn)器械的過渡期較長。
即根據(jù)產(chǎn)品風(fēng)險(xiǎn)適時(shí)制定不同過渡期。
3.原條款補(bǔ)充
第110條(Article 110)Transitional provisions修改如下:
在第二段中,日期“2024 年 5 月 27 日”替換為“2025 年 5 月 27 日”即已獲得公告機(jī)構(gòu)(NB)頒發(fā)的List A/B/Self-testing的證書有效期最遲將于2025 年 5 月 27 日失效。
原文:
Devices for which the conformity assessment procedure pursuant to Directive 98/79/EC did not require the involvement of a notified body,for which a declaration of conformity was drawn up prior to 26 May 2022 in accordance with that Directive and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body,may be placed on the market or put into service until the following dates:
(a) 26 May 2025 for class D devices;
(b) 26 May 2026 for class C devices;
(c) 26 May 2027 for class B devices;
(d) 26 May 2027 for class A devices placed on the market in sterile condition.
根據(jù)指令98/79/EC 的合格評(píng)估程序不需要指定機(jī)構(gòu)參與的器械,根據(jù)該指令在2022年5月26日之前為其起草了符合性聲明并且符合合格評(píng)定程序的器械以及根據(jù)本法規(guī)的程序需要公告機(jī)構(gòu)的參與評(píng)定的器械,可在下述截止期前投放市場(chǎng)或投入使用:
(a)2025年5月25日-D類器械;
(b)2026年5月26日-C類器械;
(c)2027年5月26日-B類器械;
(d)2027年5月26日-以無菌狀態(tài)投放市場(chǎng)的A類器械。
原文:
Devices lawfully placed on the market pursuant to Directive 98/79/EC prior to 26 May 2022 may continue to be made available on the market or put into service until 26 May 2025.
根據(jù)98/79/EC指令在2022年5月26日之前合法投放市場(chǎng)的器械可以繼續(xù)在市場(chǎng)上銷售或投入使用,直至 2025 年 5 月 26 日。
4.總結(jié)
首先要明確的是:IVDR法規(guī)生效的時(shí)間仍然是2022年5月26日,生效時(shí)間沒有延后!
4.1此次修訂采用逐步適用IVDR法規(guī)要求的方式,同時(shí)優(yōu)先考慮高風(fēng)險(xiǎn)體外診斷,將現(xiàn)有受公告機(jī)構(gòu)監(jiān)管的IVD產(chǎn)品的過渡期延長一年,到2025年5月26日。
4.2在2022年5月26日之前,所有涉及IVDD Others且投放市場(chǎng)的產(chǎn)品可以繼續(xù)銷售或使用,直至2025年5月26日。
4.3在IVDD以及IVDR下均屬于低風(fēng)險(xiǎn)的自我符合性聲明的器械特指一些儀器、提取試劑盒等,不在此次延長范圍內(nèi),仍然需要在2022年5月26日之前獲得IVDR CE注冊(cè)證書。
4.4企業(yè)還需要根據(jù)法規(guī)要求在2022年5月26日建立有關(guān)上市后監(jiān)督、市場(chǎng)監(jiān)督、警戒、經(jīng)濟(jì)運(yùn)營商和器械注冊(cè)的要求,將其現(xiàn)有的質(zhì)量體系更新至IVDR法規(guī)要求的質(zhì)量體系。
4.5對(duì)IVDR過渡期條款的調(diào)整,避免了 (EU) 2017/745和 (EU) 2017/746規(guī)定的過渡期同時(shí)結(jié)束,并減輕會(huì)員國主管當(dāng)局、通報(bào)機(jī)構(gòu)、制造商、衛(wèi)生機(jī)構(gòu)和處理醫(yī)療器械和體外診斷的其他機(jī)構(gòu)的壓力。
最后匯總各類產(chǎn)品的期限如下:
1.對(duì)于原由公告機(jī)構(gòu)發(fā)證的產(chǎn)品(List A,List B,Self-testing),最晚使用期限至2025.5.26。
2.原IVDD指令下分在others類的產(chǎn)品,如果在IVDR中分類為D類,最晚須于2025.5.26取得IVDR證書,如新冠病毒診斷試劑,等。
3.原IVDD指令下分在others類的產(chǎn)品,如果在IVDR中分類為C類,最晚須于2026.5.26取得IVDR證書,如基因篩查,腫瘤篩查,等。
4.原IVDD指令下分在others類的產(chǎn)品,如果在IVDR中分類為B類,最晚須于2027.5.26取得IVDR證書,如流感病毒,等。
5.原IVDD指令下分在others類的產(chǎn)品,如果在IVDR中分類為A類滅菌,最晚須于2027.5.26取得IVDR CE注冊(cè)證書。
6.在IVDR下分類為Class A的產(chǎn)品不在延長范圍,仍需在2022年5月26日取得IVDR CE注冊(cè)證書(注意)。
最后為各位附上該修訂案的原文鏈接,歡迎有疑問的小伙伴前來咨詢。
https://ec.europa.eu/health/sites/default/files/md_newregulations/docs/md_2017-746-regulation_2021-amendment_en.pdf